Datasheet is currently unavailable. Try again or CONTACT US
Human IgG Agarose
1 References
009-0050
10 mg
Suspension of agarose beads
ELISA, SDS-PAGE
Human
Shipping info:
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Product Details
Human IgG Whole Molecule Agarose Conjugated - 009-0050
Human IgG Whole Molecule Agarose Conjugate, Human IgG Agarose
Human
Agarose
IgG
Native Protein
Target Details
This product was prepared by coupling purified Human IgG antibody to activated agarose. Sufficient antibody capacity is provided to bind a minimum of 5 mg of anti-Human IgG antibody.
Application Details
SDS-PAGE
ELISA
- View References
Human IgG Agarose has been tested by SDS-Page and is suitable for immunoprecipitation and Immunoaffinity purifications.
Formulation
2.5 mg/mL antibody per cc agarose
0.01 M Sodium Phosphate, 0.15 M Sodium Chloride, pH 7.2
0.01% (w/v) Sodium Azide
None
Shipping & Handling
Wet Ice
Store vial at 4° C prior to opening. DO NOT FREEZE.
Expiration date is one (1) year from date of receipt.
Human IgG whole molecule Agarose Conjugated product is made from IgG, secreted as part of the adaptive immune response by plasma B cells, immunoglobulin G constitutes 75% of serum immunoglobulins. Immunoglobulin G binds to viruses, bacteria, as well as fungi and facilitates their destruction or neutralization via agglutination (and thereby immobilizing them), activation of the compliment cascade, and opsonization for phagocytosis. The whole IgG molecule possesses both the F(c) region, recognized by high-affinity Fc receptor proteins, as well as the F(ab) region possessing the epitope-recognition site. Both heavy and light chains of the antibody molecule are present.
Liu X et al. (2019). Human cytomegalovirus evades antibody-mediated immunity through endoplasmic reticulum-associated degradation of the FcRn receptor. Nat Commun.
Applications
EIA, ELISA
No test method can provide total assurance that the hepatitis B virus, hepatitis C virus, human immunodeficiency virus, or any other infectious agents are absent. Thus, all blood products, including purified proteins derived from human blood sources, should be handled at Biosafety Level 2 as recommended by the CDC\NIH manual entitled Biosafety in Microbiological and Biomedical Laboratories for potentially infectious human serum, blood specimens or proteins derived from same. Source material for the human blood product supplied to your facility has been tested for the detection of HIV antibody, Hepatitis B surface antigen, antibody to Hepatitis C, HIV 1 antigen(s), antibody to HTLV - I/II, and syphilis by FDA guidelines. All units were found to be non-reactive/negative for these tests. All human blood source material is collected in FDA licensed centers and is tested with FDA approved test kits.; This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
